
Please try another search
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. It exports its products to approximately 85 countries, including the United States, the European Union, and internationally. The company is based in Jingmen, China.
Name | Age | Since | Title |
---|---|---|---|
Yi Qian Liu | 59 | 2015 | Chairman of the Board of Directors |
Dali Chen | 60 | 2020 | CFO & Director |
Fei Long | 43 | 2020 | Secretary of the Board & Non-Independent Director |
Wenxia Zhou | 50 | 2020 | Vice Chairman & GM |
Jianqiang Shen | 52 | 2018 | Chairman of the Supervisory Board |
Jun Lu | 53 | 2020 | Employee Supervisor |
Yan Xia | 41 | 2023 | Supervisor |
Xiaomiao Zhang | 49 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review